Immunity Bio (IBRX) is a strong buy with a bullish score of 8/10 due to its exceptional revenue growth, high gross margins, and revolutionary cancer immunotherapy, despite current cash burn and high short interest.
Source Post
Is Immunitybio Inc IBRX A Good Time To Buy Now? IBRX Stock Analysis
Mar 15, 2026
The podcast discusses Immunity Bio (IBRX), a biotech company experiencing explosive revenue growth (over 1000%) driven by its novel chemotherapy-free cancer immunotherapy, Anktiva. Despite significant cash burn and a high valuation, the company boasts strong gross margins and a healthy liquidity position, suggesting it can weather the current phase. Analysts have a strong buy consensus with significant upside potential, though short interest indicates market division. The primary risks are execution and regulatory hurdles, but the potential for a paradigm shift in cancer treatment makes IBRX a compelling, albeit volatile, long-term investment.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
IBRXbuy opened Mar 15, 2026
-16.92%